Revolution Medicines, Inc.
RVMD
Kedudukan dalam Saham
#619
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Harga Saham
$193.59
Modal Pasaran
$41.49B
Perubahan (1 hari)
6.28%
Perubahan (1 tahun)
258.43%
Negara
US
Perdagangan Revolution Medicines, Inc. (RVMD)
Kategori
Healthcare
Pendapatan untuk Revolution Medicines, Inc. (RVMD)
Pendapatan pada Jun 2026 TTM: $-1.77B
Menurut laporan kewangan terkini Revolution Medicines, Inc., pendapatan semasa syarikat ialah $-1.77B. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-439.89M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-249.13M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Revolution Medicines, Inc. dari 2017 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-1.77B | 194.30% |
| 2024 | $-600.85M | 36.59% |
| 2023 | $-439.89M | 76.57% |
| 2022 | $-249.13M | 33.16% |
| 2021 | $-187.09M | 72.39% |
| 2020 | $-108.53M | 108.56% |
| 2019 | $-52.04M | 24.52% |
| 2018 | $-41.79M | 34.25% |
| 2017 | $-31.13M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -398.31% |
US
|
|
| $-3.09B | 74.58% |
US
|
|
| $-4.02B | 127.12% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -210.31% |
NL
|
